Auspex Pharmaceuticals Acquired By Teva For $3.2 Billion

La Jolla-based biopharmaceuticals developer Auspex Pharmaceuticals has agreed to be acquired by Israeli biotech firm Teva Pharmaceuticals, in a deal worth $3.2 billion in cash. The two said that Teva will pay $101.00 per shar in cash for Auspexx Pharmaceuticals. Auspex develops drugs aimed at Huntington's disease, tardive dyskinesia, and Tourette syndrome. Teva is being advised by Goldman, Sachs & Co. and Goodwin Proctor LLP in the deal; Auspex is being advised by J.P. Morgan Securities LLC and Cooley LLP.